Business Context and Reporting Period
Company: BiondVax Pharmaceuticals Ltd. (Note: Request metadata listed "Scinai Immunotherapeutics Ltd.", but the filing text identifies the registrant as BiondVax Pharmaceuticals Ltd.)
Filing Type: Form 20-F Annual Report
Period: Fiscal year ended December 31, 2015
Business Overview: BiondVax is a clinical-stage biopharmaceutical company incorporated in Israel, focused on developing M-001, a synthetic peptide-based vaccine candidate targeting seasonal and pandemic influenza strains. The company has no approved products and has not generated any revenue to date. Operations are primarily funded through equity offerings and government grants.
Key Financial Metrics (Year Ended Dec 31, 2015)
| Metric | Value (NIS '000s) | Value (USD '000s) |
|---|---|---|
| Revenue | 0 | 0 |
| Research & Development Expenses | 10,736 | 2,751 |
| Less: OCS Grant Participation | (2,830) | (725) |
| R&D Expenses (Net) | 7,906 | 2,026 |
| Marketing, General & Admin Expenses | 3,397 | 870 |
| Operating Loss | 11,303 | 2,896 |
| Net Loss | 10,199 | 2,613 |
| Cash & Cash Equivalents | 33,470 | 8,578 |
| Total Assets | 41,307 | 10,587 |
| Total Liabilities | 7,762 | 1,990 |
| Shareholders' Equity | 33,545 | 8,597 |
| Working Capital | N/A | $9,029,000 |
Note: USD conversions based on the rate of 3.902 NIS to $1.00 as of December 31, 2015.
Material Changes vs. Prior Period
- Increased R&D Spend: Gross R&D expenses increased from NIS 6.4 million in 2014 to NIS 10.7 million in 2015. This was primarily driven by higher subcontractor expenses related to preparation for a cGMP audit of the production facility.
- Higher Operating Loss: The operating loss widened to NIS 11.3 million (2015) from NIS 8.1 million (2014), reflecting increased R&D and general/administrative costs.
- Liquidity Improvement: Cash and cash equivalents increased significantly from NIS 9.6 million (2014) to NIS 33.5 million (2015). This increase is attributed to the Initial Public Offering (IPO) of ADSs on the Nasdaq Capital Market in May 2015, which generated approximately $8.54 million in net proceeds.
- Share Count: The weighted average number of shares outstanding increased to 105.5 million in 2015 from 54.3 million in 2014 due to the IPO.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- Cash Runway: Management estimates sufficient cash and commitments to fund operations for at least 15 months from the report date without additional capital.
- Capital Needs: The company does not have sufficient resources to conduct Phase 3 clinical trials independently. It intends to seek collaborations with multinational pharmaceutical companies or health authorities to finance these trials, planned for the 2017/2018 timeframe.
- Profitability: The company expects to incur substantial losses for the foreseeable future and may never become profitable.
Key Risks and Contingencies
- Regulatory Approval: M-001 is in Phase 2 clinical trials. The company faces significant risk regarding FDA approval for Phase 3 trials in the U.S. and eventual marketing approval. Failure to obtain approval would materially harm the business.
- Litigation:
- Consultant Lawsuit: A former consultant sued for wrongful termination of a consulting agreement, seeking approximately NIS 1.5 million ($380,000) and reinstatement of options. The company intends to vigorously defend the claim.
- ISA Investigation: CEO Dr. Ron Babecoff was investigated by the Israeli Securities Authority (ISA) regarding alleged insider trading by certain shareholders (not including Dr. Babecoff). He was released subject to restrictions and a bond deposit. The company approved a payment of up to NIS 400,000 to cover the bond.
- Intellectual Property: Core IP is licensed exclusively from Yeda Research and Development Company Ltd. Termination of this license would have a material adverse effect.
- Geopolitical Risk: Operations are based in Israel, exposing the company to regional political, economic, and military instability.
Investor Verification Checklist
- Cash Burn Rate: Verify the 15-month runway estimate against current quarterly cash usage, given the lack of revenue.
- Phase 2 Trial Results: Monitor the completion and results of the BVX-007 trial in Europe and the planned NIAID trial in the U.S., as these are prerequisites for Phase 3.
- Partnership Progress: Assess the company's ability to secure a strategic partner to fund the expensive Phase 3 trials, as internal funds are insufficient.
- Legal Outcomes: Track the resolution of the consultant lawsuit and the status of the ISA investigation involving the CEO.
- Grant Compliance: Review compliance with Israeli government grant requirements (OCS/Authority), particularly regarding manufacturing location and technology transfer restrictions.